Daratumumab maintenance or observation after treatment with VTd with or without DARA and ASCT in patients with newly diagnosed multiple myeloma: CASSIOPEIA 2 (https://www.myeloma.org/videos/daratumumab-maintenance-or-observation-after-treatment-vtd-asct-patients-cassiopeia)
Dr. Philippe Moreau on the CASSIOPEIA - Part 2 Study
What is the background of the study?
Daratumumab (DARA) and Velcade (bortezomib)/thalidomide/dexamethasone (DVTd) plus autologous stem cell transplant (ASCT) was approved for transplant-eligible (TE) newly diagnosed multiple myeloma based on part 1 of the CASSIOPEIA trial. We report a prespecified interim analysis of CASSIOPEIA part 2: DARA maintenance versus observation in patients with ≥partial response (PR) in part 1, regardless of induction/consolidation (ind/cons) treatment.
In this video:
Dr. Philippe Moreau (University Hospital Hotel-Dieu, Nantes, France) discusses the results of the CASSIOPEIA Part 2 study.
Conclusions:
CASSIOPEIA part 2 demonstrated a clinical benefit of DARA maintenance in TE NDMM pts, with significantly longer PFS for DARA vs OBS. With current follow-up, maintenance PFS benefit appeared only in pts treated with VTd as ind/cons. Pts who received D-VTd ind/cons with or without DARA maintenance achieved similar PFS; longer follow-up is needed for PFS2 and OS. DARA significantly increased deeper response and MRD negativity rates versus observation, and was well tolerated with no new safety signals.
Clinical trial information: NCT02541383